{"id":"W2793000301","doi":"10.1158/1538-7445.sabcs17-gs3-03","title":"Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clinical endpoint; Celecoxib; Placebo; Breast cancer; Internal medicine; Hazard ratio; Proportional hazards model; Cancer; Oncology; Clinical trial; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001672711,0.0003721201,0.0007596375,0.0001768051,0.0002887051,0.00008969408,0.0008177568,0.0002361848,0.006183366],"category_scores_gemma":[0.0003300625,0.0003569058,0.0002806108,0.0006512916,0.000444851,0.0002057395,0.0001934471,0.0009316899,0.00007980999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008003365,"about_ca_system_score_gemma":0.0009762977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009401179,"about_ca_topic_score_gemma":0.0003182556,"domain_scores_codex":[0.9958723,0.0002059034,0.001164731,0.0008454162,0.0009696659,0.0009419787],"domain_scores_gemma":[0.9964609,0.001189841,0.0004694859,0.0008275049,0.0006738969,0.0003784359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7455974,0.002653518,0.0000294515,0.0001945709,0.0001370986,0.000007089611,0.0003967104,0.000009216082,0.244231,0.000001935035,0.00153923,0.005202815],"study_design_scores_gemma":[0.7280487,0.0001545891,0.00003989397,0.0001634774,0.00005656584,4.36968e-7,0.0001086795,0.00003427897,0.2684616,0.000003635983,0.002671382,0.0002568158],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9521865,0.0001367481,0.000001166835,0.0002144727,0.0002989108,0.004017262,0.0004136113,0.00005242918,0.04267889],"genre_scores_gemma":[0.9929084,0.0003739637,0.00001067227,0.00001781311,0.001695331,0.002854225,0.0002848766,0.00008116892,0.001773519],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04090537,"threshold_uncertainty_score":0.9998883,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08332244430336941,"score_gpt":0.4029894656007412,"score_spread":0.3196670212973718,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}